First clinical experience with 225Ac-PSMA-617 demonstrates promising antitumor activity with a 63%-70% PSA>50%-response rate, 10-15 months duration of response and complete remissions in approximately ten percent of patients, some of them with enduring relapse-free survival. Nevertheless, without ...
225Ac-PSMA-617 has demonstrated good anti-tumor effect as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients. No study
Results: Seventy one patients were treated with a total of 155 cycles, of which 5 received 225Ac-PSMA-617, while the rest received 177Lu-PSMA-617 radioligand therapy. The primary objective was a PSA response. We found a significant PSA response with 46.5% of patients demonstrating a greater...
225Ac-PSMA-617 for PSMA-targeted alpha- radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941–4. https://doi.org/ 10.2967/jnumed.116.178673. Ku A, Facca VJ, Cai Z, Reilly RM. Auger electrons for cancer therapy...
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Lancet Oncol. (2018) S. Nilsson et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, ...
Recently, clinical studies using 225Ac-labeled PSMA-ligands ([225Ac]Ac-PSMA-617 or [225Ac]Ac-PSMA-I&T) have reported remarkable therapeutic results [23,24,25,26,27,28,29,30]. However, the stronger radiobiological effect of alpha particles also has implications to the organs at risk. ...
(SOC) or with SOC alone. The primary objective of this trial was to compare the radiological progression-free survival (PFS) and overall survival (OS) in the two treatment arms. Patients treated with177Lu-PSMA received [177Lu]Lu-PSMA-617 every six weeks for at least four cycles (up to ...
TPS282#Background:Actinium-225 (Ac-225)-based, prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) represents a promising treatment modality for prostate cancer. First-generation PSMA-targeting ligands (e.g., PSMA-617 and PSMA-I&T) paired with Ac-225 have been ...
The 225Ac PSMA 617 therapy was well tolerated with no serious treatment emergent adverse effect. The most common adverse effect was xerostomia. All the patients had an improvement in the quality of life. The principal improvements being in pain relief. There was no haematological toxicity or ...
Part 2 (P2) randomizes 1:1 between 45 and 60 kBq/kg in patients with CRPC without prior exposure to Lu-177-PSMA (-617 or -I&T). Part 3 (P3) is a Bayesian Optimal Interval (BOIN) design dose-escalation protocol (45, 55, and 60 kBq/kg, with optional dose expansion) for ...